Welcome to our dedicated page for Puma Biotechnology SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Puma Biotechnology reported higher fourth quarter 2025 revenue but flat full-year sales, while remaining profitable for a third straight year. Q4 2025 total revenue was $75.5 million, up from $59.1 million, driven by NERLYNX product revenue of $59.9 million and royalty revenue of $15.6 million. GAAP net income for the quarter was $13.4 million, or $0.26 per diluted share, down from $19.3 million, largely reflecting valuation allowance effects.
For full year 2025, total revenue was $228.4 million versus $230.5 million in 2024, while GAAP net income inched up to $31.1 million, or $0.61 per diluted share. Non-GAAP adjusted net income was $38.1 million. Operating cash flow strengthened to $41.8 million, and total debt declined sharply to $22.5 million from $67.0 million, improving the balance sheet.
For 2026, Puma guides total revenue to $214–$221 million and GAAP net income of $10–$13 million, implying lower profit than 2025 as it invests in R&D. The company highlighted ongoing Phase II ALISCA™-Breast1 and ALISCA™-Lung1 trials, with multiple clinical data readouts expected in 2026 alongside continued commercialization of NERLYNX.
PUMA BIOTECHNOLOGY, INC. President and CEO Alan H. Auerbach reported equity awards that increase his direct holdings. On February 18, 2026, he received a grant of stock options for 227,474 shares at an exercise price of $0.00 per share.
On the same date, he was also granted 159,778 shares of common stock in the form of restricted stock units. Both the RSUs and the options vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to continued employment and possible acceleration in certain events.
PUMA BIOTECHNOLOGY, INC. executive Douglas M. Hunt reported new equity awards consisting of stock options and restricted stock units. He was granted stock options for 70,321 shares at no exercise price shown here and 49,394 restricted stock units, both in direct ownership. These awards vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, conditioned on his continued service with the company through each vesting date.
Puma Biotechnology, Inc. reported that its Chief Financial Officer, Maximo F. Nougues, received new equity awards on February 18, 2026. He was granted a stock option for 66,541 shares at an exercise price of $0.00 per share and 46,739 Restricted Stock Units (RSUs) representing shares of common stock.
According to the award terms, both the RSUs and the option vest in four equal installments: one-fourth on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, in each case conditioned on his continued service with the company through the applicable vesting date.
Puma Biotechnology President and CEO Alan H. Auerbach, who is also a director and 10% owner of the company, reported two open-market sales of Puma common stock. On January 6, 2026, he sold 16,938 shares at a price of $5.844 per share. On January 7, 2026, he sold an additional 18,012 shares at $5.879 per share.
After these transactions, Auerbach beneficially owned 7,145,951 shares of Puma common stock directly. The filing notes that these transactions were made under a Rule 10b5-1(c) trading plan adopted on December 17, 2020, which is a pre-arranged plan intended to allow insiders to sell shares according to preset instructions.
Puma Biotechnology insider Douglas M. Hunt, Senior Vice President of Regulatory Affairs, reported two open-market sales of common stock under a pre-established Rule 10b5-1(c) trading plan. On 01/06/2026, he sold 3,973 shares at a price of $5.844 each, leaving him with 160,921 shares directly owned. On 01/07/2026, he sold another 5,014 shares at $5.879 each, after which he directly owned 155,907 shares of Puma Biotechnology common stock.
The Rule 10b5-1 plan underlying these transactions was adopted on 12-14-2020, indicating the sales were made pursuant to a pre-arranged trading instruction rather than ad hoc market timing.
Puma Biotechnology Chief Financial Officer Maximo F. Nougues reported two open-market sales of company common stock under a pre-arranged Rule 10b5-1(c) trading plan. On January 6, 2026, he sold 4,540 shares at a price of $5.844 per share, leaving him with 199,689 shares beneficially owned after that transaction. On January 7, 2026, he sold an additional 6,405 shares at $5.879 per share, resulting in 193,284 shares beneficially owned following the second sale. The filing notes that the referenced Rule 10b5-1 plan was adopted on December 14, 2020, indicating these sales were executed pursuant to that pre-established plan.
A company insider filed a Form 144 notice to sell 18,012 shares of common stock through Fidelity Brokerage Services on or about 01/07/2026, with an indicated aggregate market value of $105,892.55. The notice cites that there were 50,391,107 shares of this class outstanding, giving context for the size of the planned sale.
The shares to be sold come from restricted stock vesting on 01/02/2026, received from the issuer as compensation, with the same date shown as the payment date. In the past three months, the insider, identified as Alan Auerbach, previously sold 16,938 common shares on 01/06/2026 for $98,978.90.
Douglas Hunt filed a notice under Rule 144 to sell 5,014 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. These 5,014 shares were acquired on 01/02/2026 via restricted stock vesting from the issuer as compensation. The filing notes that 50,391,107 shares of the issuer’s common stock were outstanding. During the prior three months, Hunt sold 3,973 common shares on 01/06/2026 for gross proceeds of 24,216.62.
A shareholder filed a Rule 144 notice to sell 6,405 shares of common stock of the issuer through Fidelity Brokerage Services LLC on 01/07/2026, with an aggregate market value of $37,655.00. The filing notes that there are 50,391,107 shares of this common stock outstanding and that the shares to be sold were acquired on 01/02/2026 via restricted stock vesting as compensation from the issuer. Over the prior three months, the same seller, Maximo Nougues, sold 4,540 common shares for gross proceeds of $26,529.94. The signer represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.